secwatch / observer
8-K filed December 5, 2023, 6:59 PM ET ticker NXGL CIK 0001468929
M&A confidence high sentiment positive materiality 0.60

NEXGEL, INC. (NXGL): M&A transaction — NexGel acquires Kenkoderm psoriasis skincare line for $546,500 initial cash plus earn-out

NEXGEL, INC.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NEXGEL, INC. completed an acquisition involving Olympus Trading Company, LLC for $546,500 plus Earn-Out Payments (closed 2023-12-01).

Action
acquisition
Counterparty
Olympus Trading Company, LLC
Consideration
$546,500 plus Earn-Out Payments
Closing
2023-12-01
Exact text from the filing
tradename “Kenkoderm” (collectively, the “ Business ”). Under the terms of the Purchase Agreement and on the Closing Date, the Company paid the Seller a cash payment of $546,500 (the “ Initial Cash Payment ”). The Initial Cash Payment is not subject to any escrow conditions. Additionally, the Company shall pay the Seller a cash earn-out paid on a
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEXGEL, INC. entered into Purchase Agreement with Olympus Trading Company, LLC valued at $546,500 (effective 2023-11-30).

Action
entry
Agreement
asset purchase
Counterparty
Olympus Trading Company, LLC
Value
$546,500
Effective
2023-11-30
Exact text from the filing
On December 1, 2023 (the “ Closing Date ”), NexGel, Inc., a Delaware corporation (the “ Company ”) closed a transaction related to an Asset Purchase Agreement dated November 30, 2023 (the “ Purchase Agreement ”) with Olympus Trading Company, LLC, a Virginia limited liability company (the “ Seller ”), whereby the Company purchased all assets related to the Seller’s skincare line
View on SEC.gov

Browse all m&a transactions →

NEXGEL, INC. filing history →

Source: SEC EDGAR
accession 0001493152-23-043659
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.